Climb Bio's CLYM116 keeps APRIL suppressed for 12 weeks in Phase 1
Climb Bio reported Phase 1 data for CLYM116 showing APRIL suppression lasting 12 weeks, supporting a dosing schedule once every 12 weeks, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Climb Bio has released Phase 1 findings for its CLYM116 antibody, according to a summary of an SEC filing published by TradingView. Per the company, a single dose of 480 mg or more kept free APRIL levels down by at least 90% for 12 weeks, which could make dosing once every 12 weeks feasible.
At the 12-week mark, an 800 mg dose lowered Gd-IgA1 by roughly 70% and IgA by about 60%. The antibody's half-life was close to 33 days, and its exposure rose steadily and in proportion to dose across two studies. No serious side effects, dose-limiting toxicity or drops in immunoglobulin levels were recorded.
The Phase 2 NAVIGATE-2 trial is currently recruiting, with first readouts anticipated during the first half of 2027. A global Phase 3 study is planned to launch in 2027, subject to feedback from regulators.
why it matters
This is a single-company, early-stage update, so its direct effect on broad markets is limited. Investors will watch whether the drug's effect holds up under infrequent dosing and how its safety profile looks, with the Phase 2 readout being the main test of the program's commercial case.
tags
instruments
sources
- Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing — TradingView, 23 October 2026 at 21:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗